Total intravenous anesthesia, or TIVA, is a method of general anesthesia where medications are given strictly through a vein to make a patient sleep and feel no pain, without using any inhaled gases.
It is commonly delivered with a propofol infusion plus an analgesic such as remifentanil; propofol alone does not provide analgesia.
Propofol is the backbone hypnotic, valued for a relatively favorable context-sensitive half-time that permits clear-headed emergence even after prolonged infusion.
Pumps or manual drips push the liquid drugs continuously into the patient’s vein.
A particular safety concern is interruption of the IV infusion—for example, from a disconnected line or an infiltrated cannula—which can lead to inadequate anesthesia.
Monitoring teams track brain activity using monitors (like EEG) to make sure the patient stays safely asleep.
Main Benefits: Patients have a much lower chance of throwing up or feeling sick after surgery compared to inhaled gases.
Reduced postoperative nausea and vomiting compared with volatile anesthesia—the most consistently demonstrated benefit and a core rationale in ERAS pathways.
It leaves no smelly or polluting gases in the operating room air.
No environmental (greenhouse-gas) pollution, unlike volatile agents.
Common Uses: Used for people who have a family history of a dangerous muscle reaction to gas anesthesia (malignant hyperthermia).
Helpful during brain or nerve surgeries where doctors need precise brain wave monitoring.
Short-acting opioid — remifentanil is often preferred for its rapid onset and very short, infusion-duration-independent context-sensitive half-time (rapid ester hydrolysis, clearance >3 L/min); alfentanil, sufentanil, or fentanyl are alternatives.
Depth-of-anesthesia monitoring is strongly recommended during TIVA—particularly under neuromuscular blockade—because there is no end-tidal agent concentration to gauge delivery, raising theoretical awareness risk.
Indicated where volatiles are contraindicated or problematic: malignant hyperthermia susceptibility, certain congenital myopathies, airway/shared-airway procedures, and neuromonitoring cases (propofol preserves SSEPs and allows intracranial pressure reduction via decreased cerebral blood flow).
Both TIVA and volatile anesthesia are safe and provide adequate surgical conditions, and no single technique is consistently superior across all outcomes.
Volatile agents retain advantages in cardioprotection (myocardial preconditioning) and airway management, whereas TIVA may benefit select populations such as cancer surgery and neuroanesthesia—though evidence for oncologic and cognitive benefits remains low-strength.